XTRA:MRK Earnings and Revenue History March 14th 2025 How Do Unusual Items Influence Profit? For anyone who wants to understand Merck KGaA's profit beyond the statutory numbers, i ...
One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...
Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...
On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...
Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...
Asian News International on MSN3d
Merck Foundation CEO Together with First Ladies of Africa Mark International Women's Day 2025 Through Their 'More Than a Mother' CampaignIndia], March 11: Merck Foundation, the philanthropic arm of Merck KGaA Germany, together with First Ladies of Africa and ...
In a report released today, Matthew Weston from UBS maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of ...
Full Year 2024 Results Key Financial Results Revenue: €21.2b (flat on FY 2023). Net ...
Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsFlorian Schraeder - Head of Investor ...
The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...
Merck KGaA Trading Up 2.7 % OTCMKTS MKKGY opened at $28.96 on Tuesday. The company’s fifty day simple moving average is $29.19 and its 200-day simple moving average is $32.11.
Germany’s Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced research and development expenses in its healthcare segment and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback